Assessment of Alteration of Serum Adiponectin Levels in Migraineurs: An Interventional Case Control Study. Issue 3 (July 2020)

• Record Type: Journal Article
• Authors: Joshi, Siddarth S.; Nemichandra, S. C.; Harsha, S.; Prashant, Akila; Paneyala, Shasthara; Iqbal, Roshan; Colaco, K. Vimala Christina
• Is Part Of: Annals of neurosciences. Volume 27:Issue 3/4(2020)
• Page Start: 148
• Page End: 152
• Publication Date: 2020-07
• Subjects: Migraine -- adiponectin -- numeric pain rating scales -- headache impact test; Neurosciences -- Periodicals; Nervous system -- Diseases -- Periodicals; Nervous system -- Diseases; Neurosciences; Nervous System Diseases; Periodicals; Electronic journals; Electronic journals; Periodical; 616.8
• DOI: 10.1177/0972753121990141
• Languages: English
• ISSNs: 0972-7531

Abstract

Background and Objectives: Migraine is one of the major headache disorders. Epidemiological studies have shown its high prevalence and negative impact on personal and socioeconomic aspects. It is currently ranked 19th by the "World Health Organization" amongst all diseases, leading to disability worldwide. Inflammatory mediators, which include adipokines, have been analyzed in migraine pathophysiology. Nevertheless, their role is not well recognized. This study is aimed to assess serum high molecular weight adiponectin (HMW-ADP) levels in migraineurs: during the ictal phase, prior to, and postabortive treatment. Methods: This was a hospital-based interventional case-controlled study, checking the peripheral blood samples from migraineurs during an acute attack and after one hour of treatment with naproxen sodium (10–15 mg/kg). Age, sex, and BMI matched controls without headache were taken, and a single blood sample was drawn in them. HMW-ADP levels were evaluated by immunoassays. Results: A total of 120 patients which included 60 migraine patients along with 60 controls without headache were involved in the study. HMW-ADP was higher in migraine patients (9.89 ± 5.04 mcg/mL) than in patients without headache history (4.63 ± 2.98 mcg/mL; P = < .001); along with this, serum HMW-ADP (6.4 ± 4.09 mcg/mL; P = <.001) was found to be significantly lower in responders 60 min after acute abortive treatment. Conclusion: HMW-ADP levels were raised in migraineurs. Additionally, among responders following abortive treatment a considerable reduction in the levels was noted. These results recommend that the HMW-ADP might be a possible "novel biomarker of acute remedy response in acute migraineurs".